Table 4.
Phase II doublet combinations
| Author | Year | Drug (dose) | n = | Responses (%) | Stable disease | Response in platinum resistant |
|---|---|---|---|---|---|---|
| D ’Agostino | 2003 | PLD (30 mg/m2) q day 1 gemcitabine (1000 mg/m2) q day 1 and 8 every 21 days | 70 | 23 (34.3%) | 26 (38.8%) | 25% |
| Campos | 2003 | PLD (30 mg/m2) q 3 wk, paclitaxel (70 mg/m2) q wk | 40 | 11 (29%) | NR | 17% |
| Ferrero | 2004 | PLD (30 mg/m2) q 4 wk, carboplatin (AUC 5) q 4 wk | 105 | (63%) | NR | 0% |
| vorobiof | 2004 | PLD (50 mg/m2) q 4 wk, Carboplatin (AUC 5) q 4 wk | 21 | 13 (62.5%) | 5 (23%) | 0% |
| Ferrandina | 2005 | PLD (50 mg/m2) q 3 wk, gemcitabine (1000 mg/m2) q 3 wk | 106 | 35 (34%) | 38 (34%) | 21% |
| Kastaros | 2005 | PLD (30 mg/m2) q 3 wk, vinorelbine (30 mg/m2) q 3 wk | 32 | 13 (43%) | 8 (26.7%) | 25% |
| Skarlos | 2005 | PLD (25 mg/m2) day 1, gemcitabine (650 mg/m2) day 1 and 8, every 28 days | 37 | 8 (22%) | 2 (5.5) | 22% |
| Nicoletto | 2006 | PLD (30–35 mg/m2), oxaliplatin (70 mg/m2) q 4 wk | 41 | 22 (54%) | NR | 28.6% |
| Petru | 2006 | PLD (30 mg/m2) day 1, gemcitabine (650 mg/m2) day 1 and 8, every 28 days | 30 | 10 (33%) | NR | 10 (33%) |
| Verhaar-Langereis | 2006 | PLD (30 mg/m2), topotecan (1 mg/m2) q 3 wk | 27 | 7 (28%) | 11 (44%) | NR |
| Valerio | 2006 | PLD (30 mg/m2) oxaliplatin (85 mg/m2) cyclophosphamide (750 mg/m2) | 49 | 18 (46%) | 9 (23%) | 37% |
Abbreviations: NR, not reported; PLD, pegylated liposomal doxorubicin.